Literature DB >> 28577796

How to Define Atopic Dermatitis?

Thomas Bieber1.   

Abstract

Although atopic dermatitis (AD) is the most common skin disorder, there remains an ongoing debate on this denomination, its definition and the binary view based on immunoglobulin E measurement. The wide spectrum of the clinical phenotype of AD reflects the complex genetic and pathophysiologic mechanisms underlying the disease. The diagnostic criteria have to be reconsidered and adapted to different ethnic populations. There is an urgent need for biomarker discovery further supporting the clinical diagnostic criteria as well as the precision medicine approach on a global level.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atopic dermatitis; Definition; Eczema; Immunoglobuline E; Precision medicine

Mesh:

Substances:

Year:  2017        PMID: 28577796     DOI: 10.1016/j.det.2017.02.001

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  8 in total

1.  Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3.

Authors:  Andrew Blauvelt; Melinda Gooderham; Neal Bhatia; Richard G Langley; Shannon Schneider; John Zoidis; Azra Kurbasic; April Armstrong; Jonathan I Silverberg
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-24

2.  Pain in Atopic Dermatitis: An Online Population-based Survey.

Authors:  Flavien Huet; Jason Shourick; Sophie Séité; Charles Taïeb; Laurent Misery
Journal:  Acta Derm Venereol       Date:  2020-07-02       Impact factor: 3.875

Review 3.  Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide.

Authors:  A D Irvine; P Mina-Osorio
Journal:  Br J Dermatol       Date:  2019-05-15       Impact factor: 9.302

4.  Different definitions of atopic dermatitis: impact on prevalence estimates and associated risk factors.

Authors:  T Nakamura; S Haider; S Colicino; C S Murray; J Holloway; A Simpson; P Cullinan; A Custovic
Journal:  Br J Dermatol       Date:  2019-06-26       Impact factor: 9.302

5.  Gingival Crevicular Fluid Zinc- and Aspartyl-Binding Protease Profile of Individuals with Moderate/Severe Atopic Dermatitis.

Authors:  Fernando Valenzuela; Javier Fernández; Marcela Aroca; Constanza Jiménez; Daniela Albers; Marcela Hernández; Alejandra Fernández
Journal:  Biomolecules       Date:  2020-11-26

6.  12-month prevalence of atopic dermatitis in resource-rich countries: a systematic review and meta-analysis.

Authors:  Annika Volke; Karolin Toompere; Kaja-Triin Laisaar; Marje Oona; Anna Tisler; Annika Johannson; Kadi Kallavus; Katrin Lang; Ele Kiisk; Anneli Uusküla
Journal:  Sci Rep       Date:  2022-09-06       Impact factor: 4.996

7.  Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.

Authors:  Hidehisa Saeki; Naoko Baba; Kazuhide Oshiden; Yuji Abe; Hidetsugu Tsubouchi
Journal:  J Dermatol       Date:  2019-11-11       Impact factor: 4.005

Review 8.  Childhood atopic dermatitis as a precursor for developing attention deficit/hyperactivity disorder.

Authors:  Yang-Chun Xu; Jin-Peng Wang; Wen-Jing Zhu; Ping Li
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.